These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33039772)

  • 1. Expanded Indication for Recombinant Tissue Plasminogen Activator from 3 to 4.5 h after Onset of Stroke in Japan.
    Miyamoto Y; Aso S; Iwagami M; Morita K; Fushimi K; Hamasaki Y; Nangaku M; Doi K; Yasunaga H
    J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105341. PubMed ID: 33039772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study.
    Momosaki R; Yasunaga H; Kakuda W; Matsui H; Fushimi K; Abo M
    Cerebrovasc Dis; 2016; 42(1-2):41-8. PubMed ID: 26986718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI.
    Guo C; Bai Q; Zhao Z; Zhang J
    Cerebrovasc Dis; 2019; 48(1-2):85-90. PubMed ID: 31587000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan.
    Tanaka K; Matsumoto S; Yamada T; Nagano S; Takase KI; Hatano T; Yamasaki R; Kira JI
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104305. PubMed ID: 31405791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favourable renal outcomes after intravenous thrombolytic therapy for acute ischemic stroke: Clinical implication of kidney-brain axis.
    Chang TH; Chiu PF; Tsai CC; Chang CH; Wu CL; Kor CT; Li JR; Kuo CL; Huang CS; Chu CC; Lin CM; Chang CC
    Nephrology (Carlton); 2019 Sep; 24(9):896-903. PubMed ID: 30334303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
    Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
    J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed Dose IV rt-PA and Clinical Outcome in Ischemic Stroke Patients With Body Weight >100 kg: Pooled Data From 3 Randomized Clinical Trials.
    Majidi S; Leon Guerrero CR; Burger KM; Sigounas D; Olan WJ; Qureshi AI
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2843-2848. PubMed ID: 30076113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex and racial disparity in utilization and outcomes of t-PA and thrombectomy in acute ischemic stroke.
    Nagaraja N; Olasoji EB; Patel UK
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):104954. PubMed ID: 32807414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study.
    Xu X; Wang D; Wang F; Norton C; Liu X; Selim M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2381-2387. PubMed ID: 29778315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
    Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
    Shah S; Liang L; Kosinski A; Hernandez AF; Schwamm LH; Smith EE; Fonarow GC; Bhatt DL; Feng W; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006031. PubMed ID: 31903770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia.
    Al Khathaami AM; Al Bdah B; Tarawneh M; Alskaini M; Alotaibi F; Alshalan A; Almuhraj M; Aldaham D; Alotaibi N
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104761. PubMed ID: 32173225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
    Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the Fukuoka Stroke Registry.
    Matsuo R; Kamouchi M; Fukuda H; Hata J; Wakisaka Y; Kuroda J; Ago T; Kitazono T;
    PLoS One; 2014; 9(10):e110444. PubMed ID: 25329379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
    Tanahashi N; Yamaguchi T; Awano H; Matsuda H
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcome of patients with early complete neurological recovery after thrombolysis for acute ischemic stroke.
    Blinzler C; Breuer L; Huttner HB; Schellinger PD; Schwab S; Köhrmann M
    Cerebrovasc Dis; 2011; 31(2):185-90. PubMed ID: 21160181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.
    Pancioli AM; Adeoye O; Schmit PA; Khoury J; Levine SR; Tomsick TA; Sucharew H; Brooks CE; Crocco TJ; Gutmann L; Hemmen TM; Kasner SE; Kleindorfer D; Knight WA; Martini S; McKinney JS; Meurer WJ; Meyer BC; Schneider A; Scott PA; Starkman S; Warach S; Broderick JP;
    Stroke; 2013 Sep; 44(9):2381-7. PubMed ID: 23887841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.